Bibliography

In October 2007 a US$38 million pharmaceutical plant was set up in Uganda on a 15-acre site southwest of the capital Kampala, by the drug importer Quality Chemical Industries to produce antiretroviral drugs for the domestic market. The Indian pharmaceutical company Cipla holds a 42% stake in Quality Chemical Industries. Cipla provided the technology and the expertise to get the plant set up; the plant now provides an outlet for Cipla to produce these important drugs for the African market. In November 2009, TLG Capital acquired a 8.2% stake in the plant. Capitalworks Investment Partners of South Africa also owns an 8.2% stake. The active pharmaceutical ingredients to produce the drugs are imported from India at a lower import cost. In February 2011, Quality Chemicals Industries stated it plans to invest $80m in a two-phased expansion. The $30 m first phase of the project will expand the capacities at Quality Chemical Industries' generic AIDS and malaria-drug plants in Kampala. The remaining $50 m investment will be used to add a new production line for pharmaceutical ingredients during the second phase.